Shares of Amgen were falling Tuesday after the biotechnology company easily beat quarterly earnings estimates and lifted revenue guidance.
Third-quarter sales of inflammation drug Amjevita/Amgevita rose 30% year-over-year, bolstered by 53% volume growth, partially offset by lower prices, according to the release, while sales of Prolia, one of Amgen’s general medicine treatments, jumped 14% from a year ago, boosted by a 7% uptick in volume and higher prices.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
Arista Stock Jumps as Earnings Top EstimatesInvestors had worried about the outlook after Meta Platforms issued a more conservative capital-spending forecast than expected.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
Dow jumps more than 300 points ahead of Fed rate decision, earningsCertain parts of the economy have proved to be resilient, spurring concerns that the central bank could signal willingness to hold rates at their current level for longer than previously anticipate…
출처: nypost - 🏆 91. / 67 더 많은 것을 읽으십시오 »